Important Securities Class Action Deadline for REGENXBIO Investors Approaches in April 2026

REGENXBIO Securities Class Action Alert

As the deadline for filing a class action lawsuit approaches, investors in REGENXBIO Inc. (NASDAQ: RGNX) are being urged to take decisive action. Faruqi & Faruqi, LLP, a renowned national securities law firm, is currently investigating potential claims against the company. Notably, investors who purchased or acquired shares between February 9, 2022, and January 27, 2026, might have grounds to seek compensation for losses incurred due to misleading information disseminated by the company.

Background on the Investigation

On January 28, 2026, REGENXBIO announced a significant setback: the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its investigational gene therapy RGX-111. This decision followed preliminary findings of adverse effects in clinical trials. As a result, the company's stock experienced a sharp decline, falling by $2.40 per share, a staggering 17.9% drop, closing at $11.01.

The allegations against REGENXBIO include failure to disclose critical facts regarding the efficacy and safety of RGX-111, which not only misled investors but also impacted the financial market significantly. Such actions have raised serious concerns about compliance with federal securities laws.

Key Details for Investors

The deadline for investors to seek the role of lead plaintiff in this federal securities class action is April 14, 2026. The lead plaintiff is typically the individual or entity that has the largest financial stake in the lawsuit and is tasked with steering the litigation process on behalf of the concerned class members. Investors have the option to engage an attorney of their choice or remain a passive class member. Importantly, the potential recovery from the lawsuit remains accessible regardless of whether an individual chooses to take an active role in the case.

How to Proceed

Faruqi & Faruqi encourages those who believe they may have been affected to reach out for a consultation. Those with additional information regarding the company's conduct, particularly whistleblowers or former employees, are also urged to come forward. The firm’s senior partner, Josh Wilson, is directly available for inquiries via phone at 877-247-4292 or 212-983-9330 (Ext. 1310).

For further information on the class action, investors are directed to visit Faruqi & Faruqi's website for details and updates. This situation underscores the importance of remaining vigilant, particularly in turbulent financial scenarios where transparency and accurate reporting are paramount.

Conclusion

The upcoming deadline serves as a critical juncture for REGENXBIO investors. As more developments unfold in the lead-up to the court date, stakeholders should stay informed and take appropriate actions to protect their rights. Investors are encouraged to monitor the situation closely and consider their options carefully to ensure they are not left without recourse.

Stay connected with Faruqi & Faruqi for updates via LinkedIn, X, or Facebook as they continue to monitor this evolving situation and provide guidance to affected investors.